About: Evolution of ARDS biomarkers: Will metabolomics be the answer?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evolution of ARDS biomarkers: Will metabolomics be the answer? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evolution of ARDS biomarkers: Will metabolomics be the answer?
Creator	Donnelly, Sarah Banoei, Mohammad Cote, Andreanne Metwaly, Sayed Mourad, Ahmed Winston, Brent
Source	PMC
abstract	To date, there is no clinically agreed-upon diagnostic test for acute respiratory distress syndrome (ARDS): the condition is still diagnosed on the basis of a constellation of clinical findings, laboratory tests, and radiological images. Development of ARDS biomarkers has been in a state of continuous flux during the past four decades. To address ARDS heterogeneity, several studies have recently focused on subphenotyping the disease on the basis of observable clinical characteristics and associated blood biomarkers. However, the strong correlation between identified biomarkers and ARDS subphenotypes has yet to establish etiology; hence, there is a need for the adoption of other methodologies for studying ARDS. In this review, we will shed light on ARDS metabolomics research in the literature and discuss advances and major obstacles encountered in ARDS metabolomics research. Generally, the ARDS metabolomics studies focused on identification of differentiating metabolites for diagnosing ARDS, but they were performed to different standards in terms of sample size, selection of control cohort, type of specimens collected, and measuring technique utilized. Virtually none of these studies have been properly validated to identify true metabolomics biomarkers of ARDS. Though in their infancy, metabolomics studies exhibit promise to unfold the biological processes underlying ARDS and, in our opinion, have great potential for pushing forward our present understanding of ARDS.
has issue date	2018-10-01(xsd:dateTime)
bibo:doi	10.1152/ajplung.00074.2018
bibo:pmid	29952222
has license	no-cc
schema:url	https://doi.org/10.1152/ajplung.00074.2018
resource representing a document's title	Evolution of ARDS biomarkers: Will metabolomics be the answer?
has PubMed Central identifier	PMC7191388
has PubMed identifier	29952222
schema:publication	Am J Physiol Lung Cell Mol Physiol
resource representing a document's body	covid:PMC7191388#body_text
is schema:about of	named entity 'ARDS' named entity 'extrapulmonary' named entity 'threonine' named entity 'choline' named entity '1H-NMR' named entity 'glycine' named entity 'choline' named entity 'lactate' named entity 'collagen' named entity 'ARDS' named entity 'glutathione' named entity 'metabolite' named entity 'ARDS' named entity 'confidence interval' named entity 'biomarkers' named entity 'edema' named entity 'lung' named entity 'branched-chain amino acids' named entity 'sphingomyelin' named entity 'nuclear magnetic resonance' named entity 'underlying condition' named entity 'phenotype' named entity 'phosphatidylcholine' named entity 'ARDS' named entity 'valine' named entity 'phosphatidylserine' named entity 'fibroblasts' named entity 'study population' named entity 'ICU' named entity 'carbohydrates' named entity 'metabolomics' named entity 'ARDS' named entity 'xanthine oxidase' named entity 'ICU' named entity 'omics' named entity '0.21' named entity 'omics' named entity 'isoleucine' named entity 'ARDS' named entity 'holistic' named entity 'clinical features' named entity 'metabolomics' named entity 'BALF' named entity 'metabolomics' named entity 'pulmonary edema' named entity 'mevalonate pathway' named entity 'emergency department' named entity 'physiology' named entity 'inflammation' named entity 'serum' named entity 'liquid chromatography-mass spectrometry' named entity 'animal models' named entity 'metabolomics' named entity 'protein catabolism' named entity 'ARDS' named entity 'phenotypes' named entity 'metabolomics' named entity 'ARDS' named entity 'vitamins' named entity 'hypoxanthine' named entity 'threonine' named entity 'glycerophospholipid metabolism' named entity 'xanthine' named entity 'S.J.D.' named entity 'ARDS' named entity 'longitudinal studies' named entity 'control patients' named entity 'sample size' named entity 'tandem mass spectrometry' named entity 'metabolomics' named entity 'ARDS' named entity 'complement' named entity 'bronchoscopy' named entity 'omics' named entity 'Acute Respiratory Failure' named entity 'glutamate' named entity 'lung'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software